GlobeNewswire Inc. · Nov 14, 2022
Lifecore Biomedical Announces Completion of Corporate Name Change
Common stock expected to begin trading tomorrow under new Nasdaq ticker symbol “LFCR”
NASDAQ · LNDC
Healthcare · Drug Manufacturers - Specialty & Generic
$8.76
Down-$0.32 (-3.52%)
Updated Sep 16, 2026, 2:14 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
LNDC does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning LNDC.
LNDC research
Company profile and research snapshot.
Landec Corporation, together with its subsidiaries, designs, develops, manufactures, and sells differentiated health and wellness products for food and biomaterials markets in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. Landec Corporation was incorporated in 1986 and is headquartered in Santa Maria, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2022 | Barrington Research | Outperform | — |
| Aug 11, 2022 | Barrington Research | Outperform | — |
| Jul 20, 2022 | Stephens & Co. | Overweight | — |
| Apr 6, 2022 | Barrington Research | Market Perform | — |
| Oct 4, 2021 | Roth Capital | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Nov 14, 2022
Common stock expected to begin trading tomorrow under new Nasdaq ticker symbol “LFCR”
Zacks Investment Research · Oct 6, 2022
Landec (LNDC) delivered earnings and revenue surprises of -166.67% and 1.89%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswire Inc. · Oct 6, 2022
Lifecore segment revenues increased 8.0% to $23.7 million in fiscal 2023 first quarter versus the prior year periodLifecore segment EBITDA increased 8.1% to $2.5 million in fiscal 2023 first quarter versus the prior year periodReiterates fiscal 2023 full year guidance for LifecoreCorporate rebranding to Lifecore Biomedical continues to progress
GlobeNewswire Inc. · Sep 28, 2022
SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Landec” or the “Company”), a diversified health and wellness company focused on its growing Lifecore Biomedical (“Lifecore”) business – a fully integrated contract development and manufacturing organization (“CDMO”) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced a change to its previously announced fiscal 2023 first quarter earnings conference call date in recognition of Yom Kippur.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning LNDC.
No results
No recent SID articles mention LNDC.